Tandem Diabetes Care (TNDM) Enterprise Value (2013 - 2026)

Tandem Diabetes Care has reported Enterprise Value for 14 years, with the latest figure at -$570.3 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 54.7% year-over-year to -$570.3 million; the trailing twelve-month figure through Mar 2026 stood at -$570.3 million (down 54.7% YoY), and the FY2025 full-year result was -$292.7 million, up 33.23% from the prior year.
• Enterprise Value for Q1 2026 stood at -$570.3 million, down from -$292.7 million in the prior quarter.
• The five-year high for Enterprise Value was -$292.7 million in Q4 2025, with the low at -$635.4 million in Q1 2022.
• Historically, Enterprise Value has averaged -$481.6 million across 5 years, with a median of -$473.3 million in 2024.
• Annual changes were most pronounced in 2025 — Enterprise Value surged 33.23% — and 2026, when it plunged 54.7%.
• Tandem Diabetes Care's Enterprise Value stood at -$616.9 million in 2022, then climbed by 24.15% to -$467.9 million in 2023, then advanced by 6.32% to -$438.3 million in 2024, then surged by 33.23% to -$292.7 million in 2025, then tumbled by 94.85% to -$570.3 million in 2026.
• The last three Enterprise Value figures came in at -$570.3 million (Q1 2026), -$292.7 million (Q4 2025), and -$319.1 million (Q3 2025), per Business Quant data.